Overview

Islet After Kidney Transplant for Type 1 Diabetes

Status:
Withdrawn

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if prolonged administration of the anti TNF (tumor necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Virginia Commonwealth University

Collaborator:

University of Miami

Treatments:

Etanercept